What is the current stock price of Genfit S.A. (GNFT)?

As of the latest market data, Genfit S.A. (GNFT) is trading at $8.95. The stock has seen a gain of 4.07% today.

Does Genfit S.A. (GNFT) pay a dividend?

Based on current data, Genfit S.A. does not have a confirmed active dividend policy.

What is the market cap of Genfit S.A.?

The current market capitalization of Genfit S.A. (GNFT) is approximately unavailable.

GNFT

Genfit S.A.·Healthcare

8.95

4.070%(+0.35)

Market Closed

5.00

44.134%(−3.95)

After Hours

Last Updated: — ET

52W L: $2.5552W H: $10.00

GNFT NEWS

globenewswire.com

Apr 2

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

Lille, France; Cambridge, MA; Zurich, Switzerland; April 2, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced annual financial results for the year ended December 31, 2025 and provided a corporate update. A summary of the consolidated financial statements is included below.

globenewswire.com

Mar 9

GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 9, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted ODD to NTZ (nitazoxanide), its investigational small-molecule drug candidate developed as a new formulation for the treatment of Acute-on-Chronic Liver Failure (ACLF).

globenewswire.com

Feb 12

GENFIT to receive US$20M milestone after Ipsen's Iqirvo® exceeds the US$200M threshold in its first full year of net sales

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 12, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the strong commercial performance of Iqirvo® in its first full year on the primary biliary cholangitis (PBC) market has triggered a US$20M milestone payment from Ipsen under the companies' licensing agreement.

Company Profile

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Sector

Healthcare

Industry

Biotechnology

Employees

180

IPO Date

2019-03-27

Beta

0.87

Websitewww.genfit.com↗